ALK and lung cancer: Initially, lentiviral CRISPR-Cas9 technology was employed to knockout YY1 in multiple EGFR-mutant, KRAS-altered, or ALK-rearranged lung cancer cell lines using two independent sgRNAs (Fig. 4A), and cell viability was significantly inhibited without exception (Fig. 4B).